STEP Path A: Biotechnology
Grants Polish biotech companies and consortia up to PLN 140 million for critical-tech R&D.
If the applicant or a consortium enterprise is a special-purpose vehicle too new to show 24 months of trading and two closed financial years, the requirement shifts to its parent company instead of disqualifying the SPV outright. When a research organisation joins the consortium, the enterprise or enterprises in it must still cover at least 50% of the whole project's eligible costs -- the research…
Funds R&D projects that develop a critical technology bringing an innovative, state-of-the-art or breakthrough element with significant economic potential to the EU internal market, specifically in biotechnology, including work that protects and strengthens critical-technology value chains. A project can combine industrial research and development work, or cover development work alone.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see the timeline
Sign up free to see where teams trip up
Guides for this application
All guides →Grants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
Find grantsGovernment Grants for Startups: What Deeptech Founders Should Know
A practical guide to government grants for startups, including Grants.gov, SBIR/STTR, state programs, eligibility, fit, timelines, and when to apply.
Start hereTRL Levels Explained for Deeptech Founders
Learn what TRL levels mean, how to estimate technology readiness, and how TRL affects grants, EIC Accelerator, SBIR/STTR, funding stage, and application evidence.
More from NCBR
All grants from this funder →RAMP Joint Call 2026
🇵🇱NCBR · Poland
Co-funds Polish firms and research partners doing raw-materials R&D with EU partners.
INNOSTART - Call 2
🇵🇱NCBR · Poland
Grants first-time Innovation Coach graduates up to PLN 320,000 for their first R&D project.
CETPartnership Joint Call 2026
🇵🇱NCBR · Poland
Co-funds Polish firms and research partners doing clean-energy-transition R&D with EU partners.
FENG Smart Path — Consortium Projects
🇵🇱NCBR · Poland
Supports consortiums linking Polish enterprises with research teams to turn laboratory results into market products.
SMART Path — Projects run by consortia
🇵🇱NCBR · Poland
Grants Polish enterprise-led consortia for R&D projects that lead to a new product or process.
EUREKA 2026 Call
🇵🇱NCBR · Poland
Co-funds Polish SMEs and larger firms building market-ready tech with a partner in another EUREKA country.
Similar grants
Browse the directory →Novel Small-Molecule Antivirals for Epidemic-Potential Pathogens
🇪🇺European Commission · European Union
Funds small-molecule antivirals that expand preparedness and treatment options for future viral epidemics and pandemics.
Innovative Antimicrobials Against Resistant Pathogens
🇪🇺European Commission · European Union
Funds antibacterial and antifungal therapies that expand treatment options against antimicrobial-resistant infections.
Horizon Health: Bio-printing for Regenerative Medicine
🇪🇺European Commission · European Union
Funds €7–10M projects that advance living-cell bio-printing from laboratory proof toward regenerative medicine.
Euratom Radiation Protection Partnership (PIANOFORTE)
🇪🇺European Commission · European Union
Funds PIANOFORTE’s 2026-27 continuation, an EU radiation-safety research partnership — only for its current members and any partner who joins them.
Horizon Health: Rare Disease Partnership (ERDERA) Phase 2
🇪🇺European Commission · European Union
Funds rare-disease research calls, clinical trial networks and shared data for ERDERA's second phase — open only to the existing coordinator.
Horizon Health: Flavivirus Antibody Therapies
🇪🇺European Commission · European Union
Funds €9–10M projects that turn monoclonal antibodies into prevention and treatment options for one Flavivirus.